ers ▁has ▁been ▁considered ▁in ev itable . ▁ ▁As ▁a ▁drug ▁target ▁L path ▁Inc ▁has ▁produced ▁and ▁optimized ▁a ▁mon oc l onal ▁anti - S 1 P ▁ant ib ody ▁( S ph ing om ab ). ▁S ph ing om ab ▁can ▁abs orb ▁S 1 P ▁from ▁the ▁ext rac ell ular ▁fluid , ▁thereby ▁lower ing ▁the ▁effective ▁concentration ▁of ▁S 1 P . ▁▁ ▁is ▁an ▁experimental ▁anti - S 1 P ▁mon oc l onal ▁ant ib ody ▁that ▁has ▁had ▁a ▁phase ▁II ▁clin ical ▁trial ▁for ▁ren al ▁cell ▁car cin oma . ▁S one p ci z um ab ▁( LT 1 0 0 9 ) ▁as ▁A SON EP ▁( for ▁int ra ven ous ▁injection ) ▁has ▁been ▁studied ▁for ▁solid ▁tum ours . ▁As ▁i SON EP , ▁a ▁form ulation ▁for ▁int rav it real ▁injection , ▁it ▁has ▁been ▁studied ▁for ▁age - related ▁mac ular ▁deg ener ation . ▁ ▁S 1 P ▁re ceptor ( s ) ▁as ▁a ▁drug ▁target ▁There ▁are ▁ 5 ▁types ▁of ▁S ph ing os ine - 1 - ph osph ate ▁re ceptor . ▁ ▁S 1 P ▁re ceptor ▁mod ul ators ▁The ▁drug ▁f ing ol im od ▁( FT Y 7 2 0 ), ▁which ▁ag on izes ▁the ▁S 1 P ▁re ceptor , ▁prevents ▁auto imm une ▁l ym ph ocy tes ▁from ▁moving ▁from ▁the ▁l ym ph oid ▁org ans ▁into